Production and characterization of simian-human immunodeficiency virus- like particles

AIDS Research and Human Retroviruses

Volumn 16, Issue 3, 2000, Pages 227-236

  Yao, Qizhi ^a,b   Kuhlmann, Frederick M ^a   Eller, Ron ^a   Compans, Richard W ^a   Chen, Changyi ^b  

^a Dept of Microbiol and Immunol ^*  (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; BACULOVIRUS; BIOTINYLATION; CELL FUSION; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; INSECT; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; VIRUS MORPHOLOGY; VIRUS PARTICLE;

ANIMALS; CELL FUSION; CELL LINE; CELL MEMBRANE; GENE EXPRESSION; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENETIC VECTORS; HELA CELLS; HIV; HUMANS; NUCLEOPOLYHEDROVIRUS; RECOMBINANT FUSION PROTEINS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRION; VIRUS ASSEMBLY;

EID: 0034628631     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200309322     Document Type: Article

References (56)

1. 1. Yamshchikov GV, Ritter GD, Vey M, and Compans RW: Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology 1995;214:50-58.
2. 2. Vzorov AN and Compans RW: Assembly and release of SIV Env proteins with full-length or truncated cytoplasmic domains. Virology 1996;221:22-33.
3. 3. Deml L, Kratochwil G, Osterrieder N, Knuchel R, Wolf H, and Wagner R: Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology 1997;235:10-25.
4. 4. Deml L, Schirmbeck R, Reimann J, Wolf H, and Wagner R: Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology 1997;235:26-39.
5. 5. Bugelski PJ, Maleeff BE, Kinkner AM, Ventre J, and Hart TK: Ultrastructural evidence of an interaction between Env and Gag proteins during assembly of HIV type 1. AIDS Res Hum Retroviruses 1995;11:55-64.
6. 6. Dorfman T, Mammano F, Haseltine WA, and Gottlinger HG: Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1994; 68:1689-1696.
7. 7. Freed EO and Martin MA: Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J Virol 1995;69:1984-1989.
8. 8. Gonzales SA, Affranchino JL, Gelderblom HR, and Burny A: Assembly of the matrix protein of simian immunodeficiency virus into virus-like particles. Virology 1993;194:548-556.
9. 9. Owens RJ, Dubay J, Hunter E, and Compans RW: The human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells. Proc Natl Acad Sci USA 1991;88:3987-3991.
10. 10. Yu X, Yuan X, Matsuda Z, Lee T-H, and Essex M: The matrix protein of HIV type 1 is required for incorporation of viral envelope protein into mature virus. J Virol 1992;66:4966-4971.
11. 11. Dubay JW, Roberts SJ, Hahn BH, and Hunter E: Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol 1992; 66:6616-6625.
12. 12. Yu X, Yuan X, McLane MF, Lee T-H, and Essex M: Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions. J Virol 1993;67:213-221.
13. 13. Li J, Lord CI, Haseltine W, Letvin NL, and Sodroski J: Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr 1992;5:639-646.
14. 14. Lu S, Arthos I, Montefiori DC, Yasutomi Y, Manson K, Mustafa F, Johnson E, Santoro JC, Wissink I, Mullins JI, Haynes JR, Letvin NL, Wyand M, and Robinson HL: Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 1996;70:3978-3991.
15. 15. Sakuragi S, Shibata R, Mukai R, Komatsu T, Fukasawa M, Sakai H, Sakurasi J-I, Kawimura M, Ibuk K, Hayami M, and Adachi A: Infection of macaque monkeys with a chimeric human and simian immunodeficiency virus. J Gen Virol 1992;73:2983-2987.
16. 16. Luo L, Li Y, Chang IS, Cho SY, Kim TY, Choi MJ, Cheong HS, Kim HJ, Ahn HJ, Min MK, Chun BH, Jung SM, Woo SG, Park SY, and Kang CY: Induction of V3-specific cytotoxic T lymphocyte responses by HIV Gag particles carrying multiple immunodominant V3 epitope of gp120. Virology 1998;240:316-325.
17. 17. Griffiths JC, Harris SJ, Layton GT, Berrie EL, French TJ, Burns NR, Adams SE, and Kingsman AJ: Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: Induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion. J Virol 1993;67:3191-3198.
18. 18. Wagner R, Boltz T, Deml L, Modrow S, and Wolf H: Induction of cytolytic T lymphocyte directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses. J Gen Virol 1993;74: 1261-1269.
19. 19. Wagner R, Deml L, Schirmbeck R, Niedrig M, Reimann J, and Wolf H: Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Virology 1996;220:128-140.
20. 20. Wagner R, Teeuwsen VJP, Deml L, Notka F, Haaksma AGM, Jhagjhoorsingh SS, Niphuis H, Wolf H, and Heeney JL: Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection. Virology 1998;245:65-74.
21. 21. Valenzuela P, Medina A, Rutter WJ, Ammerer G, and Hall BD: Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature (London) 1982;298:347-350.
22. 22. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, and Hilleman MR: Human hepatitis B vaccine from recombinant yeast. Nature (London) 1984;307:178-180.
23. 23. O'Reilly DR, Muller LK, and Luckov VA: Baculovirus Expression Vectors: A Laboratory Manual. W.H. Freeman and Company, New York, 1992, pp. 130-132.
24. 24. Wells DE and Compans RW: Expression and characterization of a functional human immunodeficiency virus envelope glycoprotein in insect cells. Virology 1990;176:575-586.
25. 25. Chakrabarti L, Emerman M, Tiollais P, and Sonigo P: The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity. J Virol 1989;63:4395-4403.
26. 26. Hirsch VM, Edmondson P, Murphey-Corb M, Arbeille B, Johnson PR, and Mullins JL: SIV adaption to human cells. Nature (London) 1989;341:573-574.
27. 27. Kodama T, Wooley DP, Naidu YM, Kestler HW, Daniel MD, Li Y, and Desrosiers RC: Significance of premature stop codons in env of simian immunodeficiency virus. J Virol 1989;63:4709-4714.
28. 28. Wilk T, Pfeiffer T, and Bosch V: Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product. Virology 1992;189:167-177.
29. 29. Haffar O, Garrigues J, Travis B, Morgan P, Zarling J, and Hu S-L: Human immunodeficiency virus-like, nonreplicating, Gag-Env particles assemble in a recombinant vaccinia virus expression system. J Virol 1990;64:2653-2659.
30. 30. Ritter GD, Mulligan MJ, Lydy SL, and Compans RW: Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain. Virology 1993;197: 255-264.
31. 31. Spies CP and Compans RW: Effects of cytoplasmic domain length on cell surface expression and syncytium-forming capacity of the simian immunodeficiency virus envelope glycoprotein. Virology 1994;203:8-19.
32. 32. Johnston PB, Dubay JW, and Hunter E: Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol 1993;67:3077-3086.
33. 33. Zingler K and Littman DR: Truncation of the cytoplasmic domain of the SIV envelope glycoprotein increases Env incorporation into particles and fusogenicity and infectivity. J Virol 1993;67:2824-2831.
34. 34. Cosson P: Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J 1996;15:5783-5788.
35. 35. Gabuzda DH, Lever A, Terwillinger E, and Sodroski J: Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 1992;66:3306-3315.
36. 36. Salzwedel K, Johnson PB, Roberts SJ, Dubay JW, and Hunter E: Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins. J Virol 1993;67:5279-5288.
37. 37. Wilk T, Pfeiffer T, Bukovsky A, Moldenhauer G, and Bosch V: Glycoprotein incorporation and HIV-1 infectivity despite exchange of the gp160 membrane-spanning domain. Virology 1996;218: 269-274.
38. 38. Garnier L, Ravallec M, Blanchard P, Chaabihi H, Bossy JP, Devauchelle G, Jestin A, and Cerutti M: Incorporation of pseudorabies virus gD into human immunodeficiency virus type 1 Gag particles produced in baculovirus-infected cells. J Virol 1995;69: 4060-4068.
39. 39. Osterrieder N, Wagner R, Brandmuller C, Schmidt P, Wolf H, and Kaaden S-R: Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology 1995;208:500-510.
40. 40. Guo H-G, Veronese F, Tschachler E, Pal R, Kalyanaraman VS, Gallo RC, and Reitz MSJ: Characterization of an HIV-1 point mutant blocked in envelope glycoprotein cleavage. Virology 1990; 174:217-224.
41. 41. Kräusslich H-G, Ochsenbauer C, Traenckner A-M, Mergener K, Facke M, Gelderblom HR, and Bosch V: Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology 1993;192:605-617.
42. 42. McCune JM, Rabin LB, Feinberg MB, Leiberman M, Kosek JC, Reyes GR, and Weissman IL: Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 1988;53:55-67.
43. 43. Jenkins S, Grits L, Fedor CH, O'Neill EM, Cohen LK, and Panicali DL: Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. AIDS Res Hum Retroviruses 1991;7:991-998.
44. 44. Lee PP and Linial ML: Efficient particle formation can occur if the matrix domain of human immunodeficiency virus type 1 Gag is substituted by a myristilation signal. J Virol 1994;68:6644-6654.
45. 45. Page KA, Stearns SM, and Littman DR: Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity. J Virol 1992;66:524-533.
46. 46. Vzorov AN, Bukrinsky MI, Grigoryev VB, Tentsov YY, and Bukrinskaya AG: Highly immunogenic HIV virus-like particles are produced by recombinant vaccinia virus-infected cells. AIDS Res Hum Retroviruses 1991;7:29-36.
47. 47. Fenouillet E and Jones IM: The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp 160. J Gen Virol 1995;76:1509-1514.
48. 48. Morikawa Y, Barsov E, and Jones I: Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin. J Virol 1993;67:3601-3604.
49. 49. Radrizzani M, Accorero P, Delia D, Kurrle R, and Colombo MP: Apoptosis induced by HIV-gp120 in a Thy 1 clone involves the generation of reactive oxygen intermediates downstream CD95 triggering. FEBS Lett 1997;411:87-92.
50. 50. Pugliese O, Biorivant M, and Viora M: Apoptosis induced by human immunodeficiency virus type 1 (HIV-1) gp120 peptides. Viral Immunol 1997;10:95-102.
51. 51. Pantaleo G and Fauci A: Apoptosis in HIV infection. Nature Med 1995;1:118-120.
52. 52. Corasaniti MT, Melino G, Navarra M, Garaci E, Finazzi-Agro A, and Nistico G: Death of cultured human neuroblastoma cells induced by HIV gp120 is prevented by NMDA receptor antagonists and inhibitors of nitric oxide and cyclooxygenase. Neurodegeneration 1995;4:315-321.
53. 53. Kong LY, Wilson BC, McMillian MK, Bing G, Hudson PM, and Hong JS: The effects of the HIV-1 envelope gp120 on the production of nitric oxide and proinglammatory cytokines in mixed glial cell cultures. Cell Immun 1996;172:77-83.
54. 54. Bagetta G, Corasaniti MT, Aloe L, Berliocchi L, Costa N, Finazzi-Agro A, and Nistico G: Intracerebral injection of human immunodeficiency virus type 1 coat protein gp120 differentially affects the expression of nerve growth factor and nitric oxide synthase in the hippocampus of rat. Proc Natl Acad Sci USA 1996;93:928-933.
55. 55. Bagetta G, Corasaniti MT, Costa N, Berliocchi L, Finazzi-Agro A, and Nistico G: The human immunodeficiency virus type 1 (HIV-1) glycoprotein gp120 reduces the expression of neuronal nitric oxide synthase in the hippocampus but not in the cerebral cortex and medial septal nucleus of rat. Neurosci Lett 1997;224:75-78.
56. 56. Ilyin SE and Plata-Salaman CR: HIV-1 gp120 modulates hypothalamic cytokine mRNAs in vivo: Implications to cytokine feedback system. Biochem Biophys Res Commun 1997;231:514-518.